IPM Take
Medicine becomes vulnerable when the definition of a disease and the way a disease actually presents begin to drift apart.
Diarrhoea remains central to the clinical recognition of Clostridioides difficile infection, and that remains appropriate for the majority of patients. The new Australian analysis does not overturn that model, but it identifies a clinically important minority whose infection begins differently and whose outcomes appear worse. That is enough to ask whether diagnostic pathways are too dependent on the textbook presentation.
Executive Summary
A study published in Clinical Infectious Diseases on 25 August analysed 467 hospitalised adult episodes of C. difficile infection. Baseline gastrointestinal dysmotility was identified in 32% of episodes, while 91 of 467 cases, or 19.5%, presented without initial diarrhoea.
The absence of diarrhoea at initial presentation emerged as an independent predictor associated with increased 90-day all-cause mortality. The study is observational and does not establish that atypical presentation itself causes higher mortality, but its findings raise an important diagnostic question for hospital pathways that rely heavily on diarrhoeal illness to trigger consideration and testing for CDI.
Why it matters
- Clinicians: Atypical gastrointestinal presentations may deserve greater attention in high-risk hospitalised patients even when classic diarrhoea has not yet appeared.
- Hospitals: Diagnostic pathways should be reviewed against emerging evidence rather than assuming that conventional symptom triggers identify every clinically important case.
- Researchers: Prospective validation is needed before observational findings become broad changes in testing policy or clinical guidelines.
Few infectious diagnoses are tied as closely to a defining symptom as Clostridioides difficile infection is to diarrhoea. That relationship has shaped clinical suspicion, laboratory testing and infection-control pathways for years, for good reason: diarrhoea is the dominant presentation, and indiscriminate molecular testing can identify colonisation rather than clinically meaningful infection.
The problem is what happens when a patient genuinely has C. difficile infection but does not initially present in the way the system expects.
The new Australian study brings that question into sharper focus. Across 467 hospitalised adult CDI episodes, gastrointestinal dysmotility was common and almost one fifth of infections lacked diarrhoea at initial presentation. More importantly, atypical presentation was independently associated with increased 90-day all-cause mortality. The finding does not prove that the absence of diarrhoea causes poorer outcomes, nor does a retrospective cohort provide enough evidence to justify indiscriminate expansion of C. difficile testing. It does, however, identify a subgroup that conventional diagnostic instincts may recognise later.
That distinction matters because hospital diagnostics are built around thresholds. A symptom prompts suspicion, suspicion triggers a test, a positive result triggers treatment and infection-control measures. When the first trigger is absent, every subsequent step can move later even if the underlying pathology is already progressing.
The policy challenge is therefore more subtle than simply telling hospitals to test more people. C. difficile diagnostics already carry a well-recognised risk of overdiagnosis when highly sensitive molecular methods detect toxigenic organisms in colonised patients whose symptoms have another explanation. Expanding testing without clinical discipline could solve one problem by creating another. What the new evidence supports is a more intelligent discussion about which high-risk clinical patterns should prompt consideration of CDI before diarrhoea becomes established.
For hospitals, this is a familiar implementation problem. Clinical protocols inevitably simplify complex disease into usable pathways, because clinicians cannot operate from a blank page for every patient. Yet protocols become dangerous when their simplicity is mistaken for biological certainty. A diagnostic rule designed around the majority presentation needs enough flexibility to recognise important exceptions.
The study should therefore be treated as a strong signal rather than a finished guideline. Its findings need replication and prospective evaluation, particularly before changes are made to testing criteria that could substantially affect laboratory utilisation and isolation practices. What it already does convincingly is challenge the assumption that absence of diarrhoea reliably means absence of clinically significant CDI.
That is a useful challenge. Precision medicine is not only about identifying new biomarkers or sequencing pathogens. Sometimes it begins with recognising that the patient in front of the system does not fit the pathway that was designed for them.
